CymaBay Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.cymabay.com
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Interventions
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06060665
- Locations
- 🇺🇸
Baylor College of Medicine - Baylor Clinic, Houston, Texas, United States
🇺🇸The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT04620733
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇲🇽Consultorio de la Doctora Maria Sarai Gonzalez Huezo, Metepec, Mexico
🇺🇸UPMC Center for Liver Diseases, Pittsburgh, Pennsylvania, United States
Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406
- Conditions
- Interventions
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04467684
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC
- Conditions
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT04024813
- Locations
- 🇺🇸
University of Colorado Denver and Hospital, Aurora, Colorado, United States
🇺🇸Sutter Pacific Medical Foundation - California Pacific Medical Center, San Francisco, California, United States
🇺🇸Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT03602560
- Locations
- 🇺🇸
Henry Ford Health System, Novi, Michigan, United States
🇺🇸Liver Institute at Methodist Dallas, Dallas, Texas, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03551522
- Locations
- 🇺🇸
CymaBay Research Site, Rollingwood, Texas, United States
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03369002
- Locations
- 🇺🇸
Vrg & Noccr, Knoxville, Tennessee, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 119
- Registration Number
- NCT02955602
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, LLC, Atlanta, Georgia, United States
🇺🇸Henry Ford Health System, Novi, Michigan, United States
🇨🇦Toronto Centre for Liver Disease, Toronto, Ontario, Canada
Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02609048
- Locations
- 🇺🇸
Gastroenterology Associates of Western Michigan, PLC, d.b.a. West Michigan Clinical Research, Wyoming, Michigan, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇵🇱Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza w Bydgoszczy, Bydgoszcz, Kujawsko-pomorskie, Poland
Study to Evaluate the Effects of MBX-8025 in Patients With HoFH
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2016-03-09
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02472535
- Locations
- 🇨🇦
Ecogene-21, Chicoutimi, Quebec, Canada
🇨🇦Montreal Heart Institute, Montreal, Quebec, Canada
🇫🇷Endocrinologie metabolisme et prevention cardiovasulaire, Institut E3M et IHU cardiometabolique (ICAN), Hôpital Pitié Salpêtrière, Paris, France